KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Non Operating Income (2016 - 2025)

Nektar Therapeutics has reported Non Operating Income over the past 16 years, most recently at -$700000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$700000.0 for Q4 2025, down 111.17% from a year ago — trailing twelve months through Dec 2025 was -$9.0 million (down 527.4% YoY), and the annual figure for FY2025 was -$295000.0, up 24.36%.
  • Non Operating Income for Q4 2025 was -$700000.0 at Nektar Therapeutics, up from -$3.3 million in the prior quarter.
  • Over the last five years, Non Operating Income for NKTR hit a ceiling of $26.3 million in Q1 2022 and a floor of -$79.6 million in Q4 2021.
  • Median Non Operating Income over the past 5 years was -$1.1 million (2024), compared with a mean of -$4.0 million.
  • Biggest five-year swings in Non Operating Income: surged 1762.11% in 2022 and later crashed 8691.67% in 2025.
  • Nektar Therapeutics' Non Operating Income stood at -$79.6 million in 2021, then skyrocketed by 94.88% to -$4.1 million in 2022, then skyrocketed by 44.25% to -$2.3 million in 2023, then skyrocketed by 375.79% to $6.3 million in 2024, then crashed by 111.17% to -$700000.0 in 2025.
  • The last three reported values for Non Operating Income were -$700000.0 (Q4 2025), -$3.3 million (Q3 2025), and -$3.2 million (Q2 2025) per Business Quant data.